About Apeiron Biologics
Apeiron Biologics is a company based in Vienna (Austria) founded in 2005 was acquired by Ligand Pharmaceuticals in July 2024.. Apeiron Biologics offers products and services including Qarziba®. Apeiron Biologics operates in a competitive market with competitors including Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others.
- Headquarter Vienna, Austria
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Apeiron Biologics Ag
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Latest Funding Round
-
Investors
European Investment Bank
& 2 more
-
Employee Count
Employee Count
-
Acquired by
Ligand Pharmaceuticals
(Jul 08, 2024)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Apeiron Biologics
Apeiron Biologics offers a comprehensive portfolio of products and services, including Qarziba®. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Drug for treating cancer through targeted immunotherapy approaches.
Unlock access to complete
Unlock access to complete
Funding Insights of Apeiron Biologics
- Total Funding Total Funding
- Total Rounds 2
- Last Round Last Round
-
First Round
First Round
(28 Aug 2017)
- Investors Count 2
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May, 2020 | Amount | Private Equity Round - Apeiron Biologics | Valuation | Vienna Insurance Group |
|
| Aug, 2017 | Amount | Debt – Conventional - Apeiron Biologics | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Apeiron Biologics
Apeiron Biologics has secured backing from 3 investors, including venture fund and institutional investors. Prominent investors backing the company include European Investment Bank, Ligand Pharmaceuticals and Vienna Insurance Group. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Finance and advisory services for infrastructure projects are provided.
|
Founded Year | Domain | Location | |
|
-
|
Founded Year | Domain | Location | |
|
Pharmaceutical drugs are manufactured and developed in the United States.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Apeiron Biologics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Apeiron Biologics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Apeiron Biologics Comparisons
Competitors of Apeiron Biologics
Apeiron Biologics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| domain | founded_year | HQ Location |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| domain | founded_year | HQ Location |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed.
|
|
| domain | founded_year | HQ Location |
Small molecules are developed for cancer and skin disease treatments.
|
|
| domain | founded_year | HQ Location |
Cancer therapies are developed using selective pathway inhibitors.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Apeiron Biologics
Frequently Asked Questions about Apeiron Biologics
When was Apeiron Biologics founded?
Apeiron Biologics was founded in 2005 and raised its 1st funding round 12 years after it was founded.
Where is Apeiron Biologics located?
Apeiron Biologics is headquartered in Vienna, Austria.
What does Apeiron Biologics do?
Apeiron Biologics is developing tumour targeting antibodies for the treatment of cancer. Its drug pipeline include APN311, a chimeric antibody targeting GD2 antigen for the treatment of neuroblastoma; APN301, a monoclonal antibody hu14.18 linked with interleukin-2 (IL2) for the treatment of relapsedrefractory high-risk neuroblastoma (Phase 2); APN401, a siRNA targeting E3 ubiquitin ligase Cbl-b (Phase 1); APN411, a small molecule cancer immunotherapy in strategic collaboration with Evotec and Sanofi (preclinical). As of Dec 2016, the company has completed clinical development APN311 and its first application for marketing authorization is under review. In addition, the company has also out-licensed APN01 to GSK in 2010. APN01 is a recombinant human Angiotensin Converting Enzyme 2 (rhACE2) therapy for the treatment of various diseases with an imbalance of the renin-angiotensin system such as acute lung injury.
Who are the top competitors of Apeiron Biologics?
Apeiron Biologics's top competitors include Moderna, Jazz Pharmaceuticals and Advanced Accelerator Applications.
What products or services does Apeiron Biologics offer?
Apeiron Biologics offers Qarziba®.
Who are Apeiron Biologics's investors?
Apeiron Biologics has 3 investors. Key investors include European Investment Bank, Ligand Pharmaceuticals, and Vienna Insurance Group.